These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
328 related articles for article (PubMed ID: 28077803)
21. The role of mTOR inhibitors and HMG-CoA reductase inhibitors on young and old endothelial cell functions, critical for re-endothelialisation after percutaneous coronary intervention: an in vitro study. Korybalska K; Kawka E; Breborowicz A; Witowski J J Physiol Pharmacol; 2017 Jun; 68(3):397-405. PubMed ID: 28820396 [TBL] [Abstract][Full Text] [Related]
22. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Yu K; Toral-Barza L; Shi C; Zhang WG; Lucas J; Shor B; Kim J; Verheijen J; Curran K; Malwitz DJ; Cole DC; Ellingboe J; Ayral-Kaloustian S; Mansour TS; Gibbons JJ; Abraham RT; Nowak P; Zask A Cancer Res; 2009 Aug; 69(15):6232-40. PubMed ID: 19584280 [TBL] [Abstract][Full Text] [Related]
24. Effects of mTOR inhibitors and cytoskeletal-directed agents alone and in combination against normal and neoplastic hematopoietic cells in vitro. Trendowski M; Christen TD; Andonova AA; Narampanawe B; Thibaud A; Kusang T; Fondy TP Invest New Drugs; 2015 Dec; 33(6):1162-74. PubMed ID: 26490657 [TBL] [Abstract][Full Text] [Related]
25. Synergistic effect of mTOR inhibitor rapamycin and fluorouracil in inducing apoptosis and cell senescence in hepatocarcinoma cells. Bu X; Le C; Jia F; Guo X; Zhang L; Zhang B; Wu M; Wei L Cancer Biol Ther; 2008 Mar; 7(3):392-6. PubMed ID: 18075305 [TBL] [Abstract][Full Text] [Related]
26. Quantifying pharmacologic suppression of cellular senescence: prevention of cellular hypertrophy versus preservation of proliferative potential. Demidenko ZN; Blagosklonny MV Aging (Albany NY); 2009 Dec; 1(12):1008-16. PubMed ID: 20157583 [TBL] [Abstract][Full Text] [Related]
27. M(o)TOR of pseudo-hypoxic state in aging: rapamycin to the rescue. Leontieva OV; Blagosklonny MV Cell Cycle; 2014; 13(4):509-15. PubMed ID: 24496328 [TBL] [Abstract][Full Text] [Related]
29. Rapalogs in cancer prevention: anti-aging or anticancer? Blagosklonny MV Cancer Biol Ther; 2012 Dec; 13(14):1349-54. PubMed ID: 23151465 [TBL] [Abstract][Full Text] [Related]
30. Cell cycle arrest is not yet senescence, which is not just cell cycle arrest: terminology for TOR-driven aging. Blagosklonny MV Aging (Albany NY); 2012 Mar; 4(3):159-65. PubMed ID: 22394614 [TBL] [Abstract][Full Text] [Related]
31. Suppression of miR-19b enhanced the cytotoxic effects of mTOR inhibitors in human neuroblastoma cells. Chen Y; Tsai YH; Tseng BJ; Pan HY; Tseng SH J Pediatr Surg; 2016 Nov; 51(11):1818-1825. PubMed ID: 27492819 [TBL] [Abstract][Full Text] [Related]
32. A new trick for an old drug: mTOR inhibitor rapamycin augments the effect of fluorouracil on hepatocellular carcinoma by inducing cell senescence. Shi Y; August DA Cancer Biol Ther; 2008 Mar; 7(3):397-8. PubMed ID: 18344684 [No Abstract] [Full Text] [Related]
33. mTOR Activity and Autophagy in Senescent Cells, a Complex Partnership. Cayo A; Segovia R; Venturini W; Moore-Carrasco R; Valenzuela C; Brown N Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360912 [TBL] [Abstract][Full Text] [Related]
34. Phosphorylation of mTOR Ser2481 is a key target limiting the efficacy of rapalogs for treating hepatocellular carcinoma. Watari K; Nishitani A; Shibata T; Noda M; Kawahara A; Akiba J; Murakami Y; Yano H; Kuwano M; Ono M Oncotarget; 2016 Jul; 7(30):47403-47417. PubMed ID: 27329724 [TBL] [Abstract][Full Text] [Related]
35. Rapamycin inhibits mSin1 phosphorylation independently of mTORC1 and mTORC2. Luo Y; Liu L; Wu Y; Singh K; Su B; Zhang N; Liu X; Shen Y; Huang S Oncotarget; 2015 Feb; 6(6):4286-98. PubMed ID: 25738366 [TBL] [Abstract][Full Text] [Related]
37. MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation. Laberge RM; Sun Y; Orjalo AV; Patil CK; Freund A; Zhou L; Curran SC; Davalos AR; Wilson-Edell KA; Liu S; Limbad C; Demaria M; Li P; Hubbard GB; Ikeno Y; Javors M; Desprez PY; Benz CC; Kapahi P; Nelson PS; Campisi J Nat Cell Biol; 2015 Aug; 17(8):1049-61. PubMed ID: 26147250 [TBL] [Abstract][Full Text] [Related]
38. mTOR as a senescence manipulation target: A forked road. Saoudaoui S; Bernard M; Cardin GB; Malaquin N; Christopoulos A; Rodier F Adv Cancer Res; 2021; 150():335-363. PubMed ID: 33858600 [TBL] [Abstract][Full Text] [Related]
39. Hormetic effect of low doses of rapamycin triggers anti-aging cascades in WRL-68 cells by modulating an mTOR-mitochondria cross-talk. Mahalakshmi R; Priyanga J; Bhakta-Guha D; Guha G Mol Biol Rep; 2022 Jan; 49(1):463-476. PubMed ID: 34739690 [TBL] [Abstract][Full Text] [Related]
40. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid. Friedman MD; Jeevan DS; Tobias M; Murali R; Jhanwar-Uniyal M Oncol Rep; 2013 Oct; 30(4):1645-50. PubMed ID: 23877261 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]